* Synthetic Biologics receives USAN approval for generic
name ribaxamase for Phase 2 drug candidate SYN-004
The post BRIEF-Synthetic Biologics receives USAN approval for generic name ribaxamase for SYN-004 appeared first on NASDAQ.
BRIEF-Synthetic Biologics receives USAN approval for generic name ribaxamase for SYN-004
